Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Seong Gu, Heo"'
Autor:
Ji Hyun Lee, Seong Gu Heo, Beung‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim
Publikováno v:
Cancer Medicine, Vol 10, Iss 20, Pp 7012-7020 (2021)
Abstract Background In phase I studies, poziotinib has shown meaningful efficacy against various types of cancers. This phase 2 study aimed to investigate the efficacy and safety of poziotinib in recurrent and/or metastatic head and neck squamous cel
Externí odkaz:
https://doaj.org/article/3977330ad52d4adf994ba1df636f0c79
Autor:
Jii Bum Lee, Hyung Soon Park, Su Jin Choi, Seong Gu Heo, Ho Jung An, Hye Ryun Kim, Min Hee Hong, Sun Min Lim, Kyle Chang, Katie Quinn, Justin Odegaard, Byoung Yong Shim, Byoung Chul Cho
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: The clinical utility of plasma tumor mutational burden (pTMB) requires further validation. Herein, the pTMB and genetic alterations were investigated as predictive biomarkers for anti-PD-1 monotherapy outcome in metastatic non-small cell
Externí odkaz:
https://doaj.org/article/6a739680d9794f76b002dee801021451
Autor:
Wongeun Lee, Dong Kwon Kim, Chun-Bong Synn, Hee Kyu Lee, Sungho Park, Dong-Sik Jung, Yewon Choi, Jae Hwan Kim, Youngseon Byeon, Young Seob Kim, Seul Lee, Soyeon Lee, Yunjoo Joo, Eun Ji Lee, Mi Ran Yun, Seong Gu Heo, Wookyeom Yang, Ji Eun Jung, Eun Kyung Kim, Jooyeon Park, June Dong Park, Doo Jae Lee, Hyeon-Woo Kim, Sun Min Lim, Min Hee Hong, Beung-Chul Ahn, Jii Bum Lee, Kyoung-Ho Pyo
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
A recently developed treatment strategy for lung cancer that combines immune checkpoint inhibitors with chemotherapy has been applied as a standard treatment for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), and it has improved
Externí odkaz:
https://doaj.org/article/407f5970dae34dc5907c67d56bd5e79e
Autor:
Sun Min Lim, San-Duk Yang, Sangbin Lim, Seong Gu Heo, Stetson Daniel, Aleksandra Markovets, Rafati Minoo, Kyoung-Ho Pyo, Mi Ran Yun, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Introduction: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that is approved for the use of EGFR -mutant non-small cell lung cancer (NSCLC) patients. In this study, we investigated the acquired resistance mechanisms in NSCLC
Externí odkaz:
https://doaj.org/article/2422d3288270447897efe41264d6b211
Autor:
Chun‐Bong Synn, Sung Eun Kim, Hee Kyu Lee, Min‐Hwan Kim, Jae Hwan Kim, Ji Min Lee, Ha Ni Jo, Wongeun Lee, Dong Kwon Kim, Youngseon Byeon, Young Seob Kim, Mi Ran Yun, Chae‐Won Park, Jiyeon Yun, Sangbin Lim, Seong Gu Heo, San‐Duk Yang, Eun Ji Lee, Seul Lee, Hunmi Choi, You Won Lee, Jae Seok Cho, Do Hee Kim, Sungho Park, Jung‐Ho Kim, Yewon Choi, Sung Sook Lee, Beung‐Chul Ahn, Chang Gon Kim, Sun Min Lim, Min Hee Hong, Hye Ryun Kim, Kyoung‐Ho Pyo, Byoung Chul Cho
Publikováno v:
Clinical & Translational Immunology, Vol 11, Iss 1, Pp n/a-n/a (2022)
Abstract Objectives AXL‐mediated activation of aberrant tyrosine kinase drives various oncogenic processes and facilitates an immunosuppressive microenvironment. We evaluated the anti‐tumor and anti‐metastatic activities of SKI‐G‐801, a sma
Externí odkaz:
https://doaj.org/article/2810ccf729dc4cf68402dc5c21aa1ea6
Autor:
Seok-Young Kim, Ji Yeon Lee, Dong Hwi Kim, Hyeong -Seok Joo, Mi Ran Yun, Dongmin Jung, Jiyeon Yun, Seong Gu Heo, Beung -Chul Ahn, Chae Won Park, Kyoung Ho Pyo, You Jin Chun, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Abstract Adequate preclinical model and model establishment procedure are required to accelerate translational research in lung cancer. We streamlined a protocol for establishing patient-derived cells (PDC) and identified effective targeted therapies
Externí odkaz:
https://doaj.org/article/a381d185621a4cc6965c977aa42e9fc1
Autor:
Seung Yeon Oh, You Won Lee, Eun Ji Lee, Jae Hwan Kim, YoungJoon Park, Seong Gu Heo, Mi Ra Yu, Min Hee Hong, John DaSilva, Christopher Daly, Byoung Chul Cho, Sun Min Lim, Mi Ran Yun
Publikováno v:
Clinical Cancer Research. 29:221-232
Purpose: MET amplification is a frequent mechanism of resistance to EGFR tyrosine kinase inhibitors (TKI) in patients with EGFR-mutated non–small cell lung cancer (NSCLC), and combined treatment with EGFR TKIs and MET TKIs has been explored as a st
Autor:
Mi Ran Yun, Sun Min Lim, Byoung Chul Cho, Christopher Daly, John DaSilva, Min Hee Hong, Mi Ra Yu, Seong Gu Heo, YoungJoon Park, Jae Hwan Kim, Eun Ji Lee, You Won Lee, Seung Yeon Oh
(A-B) The surface expression levels of EGFR, MET, REGN5093 and IgG4 control of each cell were measured by flow cytometry. MFI stands for mean fluorescence intensity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44c77650d89265a11283b4a2cc94a117
https://doi.org/10.1158/1078-0432.22489169
https://doi.org/10.1158/1078-0432.22489169
Autor:
Mi Ran Yun, Sun Min Lim, Byoung Chul Cho, Christopher Daly, John DaSilva, Min Hee Hong, Mi Ra Yu, Seong Gu Heo, YoungJoon Park, Jae Hwan Kim, Eun Ji Lee, You Won Lee, Seung Yeon Oh
Whole Exom Sequencing_Somatic Mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::243402fef21e6cfbac685fc19590c908
https://doi.org/10.1158/1078-0432.22489160.v1
https://doi.org/10.1158/1078-0432.22489160.v1
Autor:
Mi Ran Yun, Sun Min Lim, Byoung Chul Cho, Christopher Daly, John DaSilva, Min Hee Hong, Mi Ra Yu, Seong Gu Heo, YoungJoon Park, Jae Hwan Kim, Eun Ji Lee, You Won Lee, Seung Yeon Oh
Information of ATCC cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::909883419602ced4177d07ddf3bfd058
https://doi.org/10.1158/1078-0432.22489157.v1
https://doi.org/10.1158/1078-0432.22489157.v1